Group A streptococcus (GAS) is a bacteria that causes a wide range of disease in humans. GAS diseases are more common in Australias Indigenous population, and other health and economically disadvantaged groups than more affluent groups. In this study we will evaluate the effectiveness of novel vaccine candidates designed to prevent infection from all strains of GAS.
Optimising Rotavirus Vaccine Effectiveness In Aboriginal Children: A Double Blinded Randomised Trial Of Rotavirus Vaccine Given To Infants 6 To 12 Months Old.
Funder
National Health and Medical Research Council
Funding Amount
$2,333,318.00
Summary
Rotavirus is major cause of diarrhoeal illness in children. A vaccine to protect against rotavirus was introduced into Australia in 2006/7. Unfortunately vaccine protection is lowest in those in whom disease rates are highest, including Aboriginal infants in the Northern Territory. This trial will investigate if offering an additional dose of vaccine between 6 to 12 months is an effective way to improve vaccine protection and thereby reduce this disease disparity.
Evaluation Of Outcomes And Cost-effectiveness Of Implementing Next Generation Human Papillomavirus (HPV) Vaccination And Associated Primary HPV-based Cervical Cancer Screening Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$697,071.00
Summary
This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new va ....This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.Read moreRead less
Schistosomiasis is a major public health problem in the Philippines with approximately 6.7 million people at risk of infection. Mass human chemotherapy has formed the cornerstone of control for decades but has failed to control the disease. Transmission reduction is a key step towards elimination and integrated interventions should target both definitive and intermediate host transmission pathways. We propose to trial integrated control strategies for the disease and expect the outcomes to have ....Schistosomiasis is a major public health problem in the Philippines with approximately 6.7 million people at risk of infection. Mass human chemotherapy has formed the cornerstone of control for decades but has failed to control the disease. Transmission reduction is a key step towards elimination and integrated interventions should target both definitive and intermediate host transmission pathways. We propose to trial integrated control strategies for the disease and expect the outcomes to have broader implications for Southeast Asia.Read moreRead less
A Self-assembling And Self-adjuvanting Nanoparticular Therapeutic Vaccine Against Cervical Cancer
Funder
National Health and Medical Research Council
Funding Amount
$387,858.00
Summary
One in every three Australians will be diagnosed with cancer in their lifetime according to the Australia Cancer Foundation. The proposed project aims to develop pathogen-like bullets based on self-organized nanoparticles which would become a strong weapon against cervical cancer.